Amcenestrant is an Orally Active SERD for Breast Cancer Research
Amcenestrant is an orally active, nonsteroidal and selective estrogen receptor degrader (SERD) for breast cancer research.
Amcenestrant is an orally active, nonsteroidal and selective estrogen receptor degrader (SERD) for breast cancer research.
There are two different forms of the estrogen receptor ERα and ERβ. Acolbifene (EM-652) is an orally active selective estrogen receptor antagonist. In particular, Acolbifene is a cancer-preventing selective estrogen…
Estrogen receptor (ER) is a ligand-induced intracellular transcription factor that mediates the biological effects of estrogen at the level of most gene regulation. The biological effect of estrogen is mediated…
Tamoxifen is a nonsteroidal agent and competitively binds to estrogen receptors (ER). This compound itself is a prodrug and it has a relatively little affinity for ER. However, tamoxifen can…
Estrogen receptor (ERs) is a group of proteins found in cells and is activated by estrogen. Specifically, ERs are typical members of the nuclear receptor superfamily, including receptors that mediate…
Estrogens participate in numerous physiological processes such as cell growth, reproduction, and differentiation. In females, the ovaries are the major site of estrogen synthesis producing the predominant estrogen 17b-estradiol (E2).…
Prostate cancer drugs targeting the androgen receptor (AR) are mainly competitive ligand-binding domain (LBD) binding antagonists. A common mechanism of drug resistance can inactivate it. Specifically, AR is a nuclear…
In previous blogs, I have introduced some compounds based on PROTAC technology, including SJFδ, MS4077, BSJ-03-123, A1874, HJB97, Olutasidenib. Today, I’d like to introduce another novel compound ERD-308 as a…